Strensiq® promoted substantial improvements in hypophosphatasia (HPP)-related rickets in patients with perinatal/infantile- and juvenile-onset hypophosphatasia.1
RGI-C scale
Hypophosphatasia-related rickets was assessed using the RGI-C scale.1,14

RGI-C evaluates change in paired radiographs of the chest and bilateral wrists and knees1,14
Scores measure change from baseline at prespecified time points14
An example of substantial healing of hypophosphatasia-related rickets10,15,a
There were insufficient data to determine the effect of Strensiq on fractures in patients with perinatal/infantile- and juvenile-onset hypophosphatasia1
aHypophosphatasia-related rickets was assessed in patients with perinatal/infantile-onset hypophosphatasia in Studies 1, 2, and 3 using the RGI-C scale.1bRadiographs are from a patient in Study 1.10
Example of a responder showing substantial healing of hypophosphatasia-related rickets10,15,a
aRadiographs are from a patient in Study 1.10
Results in juvenile-onset hypophosphatasia
100% (8/8) of patients with juvenile-onset hypophosphatasia treated with Strensiq® had substantial or complete healing of hypophosphatasia-related rickets.1,a
Patients with substantial or complete healing of hypophosphatasia-related rickets1,a

Example of a responder showing substantial healing of hypophosphatasia-related rickets10,15,a
aRadiographs are from a patient in Study 3.16